| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/28/2003 | CA2110556C The elucidation and synthesis of antineoplastic tetrapeptide phenylamides of dolastatin 10 |
| 01/28/2003 | CA2110555C Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| 01/28/2003 | CA2084799C Method of prevention of prostatic carcinoma with 17 beta-n-monosubstituted-carbamoyl-4-aza-5 alpha-androst-1 -en-3-ones |
| 01/28/2003 | CA2083534C Indolopyrrolocarbazole derivatives |
| 01/27/2003 | WO2002010127A1 Acetamide derivatives and the use thereof as inhibitors of coagulation factors xa and viia |
| 01/27/2003 | WO2002009745A1 Medicament for the immunotherapy of malignant tumours |
| 01/27/2003 | CA2417427A1 Acetamide derivatives and the use thereof as inhibitors of coagulation factors xa and viia |
| 01/27/2003 | CA2417374A1 Medicament for the immunotherapy of malignant tumours |
| 01/24/2003 | WO2002010145A1 Urethane derivatives |
| 01/24/2003 | WO2002008456A2 Method for identifying metastatic tumor cells |
| 01/24/2003 | CA2417268A1 Urethane derivatives |
| 01/24/2003 | CA2416697A1 Method for identifying metastasizing tumor cells |
| 01/23/2003 | WO2003006996A2 Natural ligand of gpcr chemr23 and uses thereof |
| 01/23/2003 | WO2003006995A2 Method for identifying substances which modulate interleukin 4 (il-4) signaling |
| 01/23/2003 | WO2003006688A2 Methods for diagnosis and treatment of diseases associated with altered expression of gnas |
| 01/23/2003 | WO2003006662A1 Anti-neoplastic viral agents |
| 01/23/2003 | WO2003006657A2 Gene-regulatory elements for gene therapy, for the prevention and diagnosis of metastases and for the gene therapy of tumours |
| 01/23/2003 | WO2003006646A1 Regulation of human aminopeptidase n |
| 01/23/2003 | WO2003006645A2 Method and composition for inhibiting heparanase activity |
| 01/23/2003 | WO2003006640A1 A specific proliferation in tumour cell which can express antioncogene with high efficiency and the use of it |
| 01/23/2003 | WO2003006636A1 Reduction of the stimulatory capacity of antigen-presenting cells |
| 01/23/2003 | WO2003006634A2 Use of oxidised lipoproteins for differentiation of precursor cells into mature dendritic cells |
| 01/23/2003 | WO2003006611A2 GPCs AS MODIFIERS OF THE IRRTK AND p21 PATHWAYS AND METHODS OF USE |
| 01/23/2003 | WO2003006509A2 Human mini-antibody cytotoxic for tumor cells which express the erbb2 receptor |
| 01/23/2003 | WO2003006508A1 A monoclonal antibody, methods of producing it and the use thereof |
| 01/23/2003 | WO2003006500A1 Method for obtaining a tgf-beta enriched protein fraction in activated form, protein fraction and therapeutic applications |
| 01/23/2003 | WO2003006495A2 Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket |
| 01/23/2003 | WO2003006492A2 Biologically active peptides |
| 01/23/2003 | WO2003006491A2 Peptide-based compounds for targeting intergin receptors |
| 01/23/2003 | WO2003006478A1 Oligonucleotide-containing pharmacological compositions and their use |
| 01/23/2003 | WO2003006477A1 IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING |
| 01/23/2003 | WO2003006459A1 Piperazine oxime derivatives having nk-1 receptor antagonistic activity |
| 01/23/2003 | WO2003006457A1 Variolin derivatives and their use as antitumor agents |
| 01/23/2003 | WO2003006447A2 Interaction inhibitors of tcf-4 with beta-catenin |
| 01/23/2003 | WO2003006444A2 Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity |
| 01/23/2003 | WO2003006434A1 Metal complexes for use in boron neutron capture therapy |
| 01/23/2003 | WO2003006430A1 Taxol enhancer compounds |
| 01/23/2003 | WO2003006428A1 Taxol enhancer compounds |
| 01/23/2003 | WO2003006425A2 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 01/23/2003 | WO2003006424A1 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 01/23/2003 | WO2003006104A2 Lymphatic endothelial cells materials and methods |
| 01/23/2003 | WO2003006070A2 Improved chelator conjugates |
| 01/23/2003 | WO2003006064A1 Pharmaceutical formulation for the intramuscular administration of fulvestrant |
| 01/23/2003 | WO2003006063A2 Formulation comprising fulvestrant |
| 01/23/2003 | WO2003006059A1 Vegfr-1 antibodies to treat breast cancer |
| 01/23/2003 | WO2003006055A2 Methods for promoting antigen presentation and modulating immune responses using cholera toxin and its b subunit |
| 01/23/2003 | WO2003006049A1 Gonadotropin releasing hormone antagonists in gel-forming concentrations |
| 01/23/2003 | WO2003006048A1 Combination of chips (chemotaxis inhibiting protein from staphylococcus aureus)-based compounds |
| 01/23/2003 | WO2003006041A1 Preventives/remedies for malignant tumor |
| 01/23/2003 | WO2003006036A2 Herbal formulation |
| 01/23/2003 | WO2003006034A2 Herbal formulation |
| 01/23/2003 | WO2003006033A2 Herbal formulation |
| 01/23/2003 | WO2003006031A1 Calcium salts with cytotoxic activity |
| 01/23/2003 | WO2003006029A1 Method of inducing apoptosis in cancer cells |
| 01/23/2003 | WO2003006027A1 Combination of drospirenone and an estrogen sulphamate for hrt |
| 01/23/2003 | WO2003006010A1 Aerosol formulations of δ8 tetrahydrocannabinol |
| 01/23/2003 | WO2003006002A1 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
| 01/23/2003 | WO2003005999A2 Methods of treating cytokine mediated diseases |
| 01/23/2003 | WO2003005989A2 Granulates containing liposoluble substances and a process for the preparation thereof |
| 01/23/2003 | WO2003005971A2 Tetracycline compounds having target therapeutic activities |
| 01/23/2003 | WO2003005965A2 Modulators of ceramidase and methods of use based thereon |
| 01/23/2003 | WO2003005964A2 Recombinant vsv for the treatment of tumor cells |
| 01/23/2003 | WO2003005962A2 Methods for treatment of cognitive and menopausal disorders with d-threo methylphenidate |
| 01/23/2003 | WO2003005961A2 A controlled release biodegradable gel matrix |
| 01/23/2003 | WO2003005955A2 Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus |
| 01/23/2003 | WO2003005952A2 Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres |
| 01/23/2003 | WO2002083159B1 Palliative effects of morinda citrifolia oil and juice |
| 01/23/2003 | WO2002072827A9 Traf3-binding b cell-specific receptor |
| 01/23/2003 | WO2002070676A3 Use of protein histidine phosphatase |
| 01/23/2003 | WO2002066475A3 Tricyclic androgen receptor modulator compounds |
| 01/23/2003 | WO2002060476A3 Tumor vaccine |
| 01/23/2003 | WO2002060436A3 Use of fredericamycin a and its derivatives in the treatment of pin1-associated states |
| 01/23/2003 | WO2002056790A3 Delivery of therapeutic capable agents |
| 01/23/2003 | WO2002055530A3 Transcobalamin binding conjugates useful for treating abnormal cellular proliferation |
| 01/23/2003 | WO2002055491A3 1,2-DISUBSTITUTED CYCLIC INHIBITORS OF MATRIX METALLORPROTEASES AND TNF-$g(a) |
| 01/23/2003 | WO2002053711A3 Use of transcription factor yb-1 in adenoviral systems |
| 01/23/2003 | WO2002050066A3 Pyrazole compounds useful as protein kinase inhibitors |
| 01/23/2003 | WO2002046171A3 Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto |
| 01/23/2003 | WO2002044174A3 3-(2,4-dimethylthiazol-5-yl) indeno[1,2-c]pyrazol-4-one derivatives as cdk inhibitors |
| 01/23/2003 | WO2002041835A3 Estrogen receptor modulators |
| 01/23/2003 | WO2002040651A3 A human trna-specific adenosine deaminase |
| 01/23/2003 | WO2002040498A3 Reduction of antioxidant enzyme levels in tumor cells using antisense oligonucleotides |
| 01/23/2003 | WO2002036741A3 Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme |
| 01/23/2003 | WO2002033095A3 Regulation of human serine-threonine protein kinase |
| 01/23/2003 | WO2002029057A3 32144, a human fatty acid amide hydrolase and uses thereof |
| 01/23/2003 | WO2002022659A3 DISCRIMINATION BETWEEN GnRH-I AND GnRH-II |
| 01/23/2003 | WO2002020619A3 HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3) |
| 01/23/2003 | WO2002018585A3 Packaging of positive-strand rna virus replicon particles |
| 01/23/2003 | WO2002016939A3 Methods of diagnosis of cancer and screening for cancer modulators |
| 01/23/2003 | WO2002012272A3 Therapeutic anti-melanoma compounds |
| 01/23/2003 | WO2002010405A3 A human disintegrin protein |
| 01/23/2003 | WO2002010363A3 Protein phosphatases |
| 01/23/2003 | WO2002008293A3 Multivalent target binding protein |
| 01/23/2003 | WO2002008177A2 N-substituted-1-amino-1,1-dialkylcarboxylic acid derivatives |
| 01/23/2003 | WO2002004946A3 Methods for identifying combinations of drugs |
| 01/23/2003 | WO2002002771A3 Human sparc-homologous (hsparc-h1) gene and methods and uses thereof |
| 01/23/2003 | WO2002002607A3 Acid-modified arabinogalactan protein composition |
| 01/23/2003 | WO2001097843A3 Methods for enhancing antibody-induced cell lysis and treating cancer |
| 01/23/2003 | WO2001093851A3 Compositions and methods for treating neoplastic disease using inhibitors of laminin5beta3 |
| 01/23/2003 | WO2001088124A3 Method and reagent for the inhibition of erg |